Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linong Ji

Showing results (371-380 of 588) with videos related to

Pageof 59
Sort By:
Diabetes|October 23, 2012
Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional studyZhiguang Zhou, Yufei Xiang, Linong Ji, et al.
The Journal of Clinical Endocrinology and Metabolism|March 22, 2017
Clinical and Genetic Features of Patients With Type 2 Diabetes and Renal GlycosuriaSiqian Gong, Jiandong Guo, Xueyao Han, et al.
Diabetes, Obesity & Metabolism|October 19, 2020
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trialLinong Ji, Xiaolin Dong, Yiming Li, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 29, 2021
A Guideline-Based Decision Tree Achieves Better Glucose Control with Less Hypoglycemia at 3 Months in Chinese Diabetic PatientsYingying Luo, Hong Wu, Xiyang Liao, et al.
Cardiovascular Diabetology|April 7, 2016
Association between socioeconomic status and metabolic control and diabetes complications: a cross-sectional nationwide study in Chinese adults with type 2 diabetes mellitusXiaoming Tao, Jihu Li, Xiaolin Zhu, et al.
Clinical Drug Investigation|September 22, 2017
Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes MellitusYitong Wang, Bingfeng Xu, Lixia Zhu, et al.
Frontiers in Endocrinology|December 5, 2025
Morning spot urinary cortisol-to-creatinine ratio: a novel screening tool for assessing excess cortisol secretionYingning Liu, Ping Zhang, Simin Zhang, et al.
Diabetes, Obesity & Metabolism|February 18, 2026
Unveiling glycaemic variability patterns linked to the triglyceride-glucose index in type 2 diabetes: Insights from continuous glucose monitoringYunxiao Wu, Kexin Feng, Yue Fu, et al.
Signal Transduction and Targeted Therapy|February 27, 2026
Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trialLinong Ji, Leili Gao, Junhang Tian, et al.
Journal of Endocrinological Investigation|June 26, 2014
Hyperglycemia and duration of diabetes as risk factors for abnormal lipids: a cross sectional survey of 19,757 patients with type 2 diabetes in ChinaLinong Ji, Jianping Weng, Juming Lu, et al.
Pageof 59

Showing results (371-380 of 588) with videos related to

Sort By:
Pageof 59
Diabetes|October 23, 2012
Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional studyZhiguang Zhou, Yufei Xiang, Linong Ji, et al.
The Journal of Clinical Endocrinology and Metabolism|March 22, 2017
Clinical and Genetic Features of Patients With Type 2 Diabetes and Renal GlycosuriaSiqian Gong, Jiandong Guo, Xueyao Han, et al.
Diabetes, Obesity & Metabolism|October 19, 2020
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trialLinong Ji, Xiaolin Dong, Yiming Li, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 29, 2021
A Guideline-Based Decision Tree Achieves Better Glucose Control with Less Hypoglycemia at 3 Months in Chinese Diabetic PatientsYingying Luo, Hong Wu, Xiyang Liao, et al.
Cardiovascular Diabetology|April 7, 2016
Association between socioeconomic status and metabolic control and diabetes complications: a cross-sectional nationwide study in Chinese adults with type 2 diabetes mellitusXiaoming Tao, Jihu Li, Xiaolin Zhu, et al.
Clinical Drug Investigation|September 22, 2017
Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes MellitusYitong Wang, Bingfeng Xu, Lixia Zhu, et al.
Frontiers in Endocrinology|December 5, 2025
Morning spot urinary cortisol-to-creatinine ratio: a novel screening tool for assessing excess cortisol secretionYingning Liu, Ping Zhang, Simin Zhang, et al.
Diabetes, Obesity & Metabolism|February 18, 2026
Unveiling glycaemic variability patterns linked to the triglyceride-glucose index in type 2 diabetes: Insights from continuous glucose monitoringYunxiao Wu, Kexin Feng, Yue Fu, et al.
Signal Transduction and Targeted Therapy|February 27, 2026
Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trialLinong Ji, Leili Gao, Junhang Tian, et al.
Journal of Endocrinological Investigation|June 26, 2014
Hyperglycemia and duration of diabetes as risk factors for abnormal lipids: a cross sectional survey of 19,757 patients with type 2 diabetes in ChinaLinong Ji, Jianping Weng, Juming Lu, et al.
Pageof 59